OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
Bernt Johan von Scholten, Frederik Flindt Kreiner, Søren Rasmussen, et al.
Therapeutic Advances in Endocrinology and Metabolism (2022) Vol. 13
Open Access | Times Cited: 23
Bernt Johan von Scholten, Frederik Flindt Kreiner, Søren Rasmussen, et al.
Therapeutic Advances in Endocrinology and Metabolism (2022) Vol. 13
Open Access | Times Cited: 23
Showing 23 citing articles:
Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities
Francesco Patera, Leonardo Gatticchi, Barbara Cellini, et al.
Biomolecules (2024) Vol. 14, Iss. 1, pp. 137-137
Open Access | Times Cited: 15
Francesco Patera, Leonardo Gatticchi, Barbara Cellini, et al.
Biomolecules (2024) Vol. 14, Iss. 1, pp. 137-137
Open Access | Times Cited: 15
Interkingdom signaling between gastrointestinal hormones and the gut microbiome
Xinyu Zhao, Ye Qiu, Lanfan Liang, et al.
Gut Microbes (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Xinyu Zhao, Ye Qiu, Lanfan Liang, et al.
Gut Microbes (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 2
Orforglipron (LY3502970 ), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
Edward Pratt, Xiaosu Ma, Rong Liu, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 9, pp. 2642-2649
Open Access | Times Cited: 26
Edward Pratt, Xiaosu Ma, Rong Liu, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 9, pp. 2642-2649
Open Access | Times Cited: 26
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell, Katharine Barnard‐Kelly, Tadej Battelino, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Oliver Schnell, Katharine Barnard‐Kelly, Tadej Battelino, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials
Jui‐Yi Chen, Tsuen‐Wei Hsu, Jung-Hua Liu, et al.
American Journal of Kidney Diseases (2025)
Open Access | Times Cited: 1
Jui‐Yi Chen, Tsuen‐Wei Hsu, Jung-Hua Liu, et al.
American Journal of Kidney Diseases (2025)
Open Access | Times Cited: 1
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications
Amedeo Lonardo, Alessandro Mantovani, Giovanni Targher, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13320-13320
Open Access | Times Cited: 37
Amedeo Lonardo, Alessandro Mantovani, Giovanni Targher, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13320-13320
Open Access | Times Cited: 37
Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
Frederik Flindt Kreiner, Philip Andreas Schytz, Hiddo J.L. Heerspink, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2498-2498
Open Access | Times Cited: 14
Frederik Flindt Kreiner, Philip Andreas Schytz, Hiddo J.L. Heerspink, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2498-2498
Open Access | Times Cited: 14
Unlocking the Multifaceted Roles of GLP-1: Physiological Functions and Therapeutic Potential.
Tohada M. AL‐Noshokaty, Rehab Abdelhamid, Nourhan M. Abdelmaksoud, et al.
Toxicology Reports (2025) Vol. 14, pp. 101895-101895
Open Access
Tohada M. AL‐Noshokaty, Rehab Abdelhamid, Nourhan M. Abdelmaksoud, et al.
Toxicology Reports (2025) Vol. 14, pp. 101895-101895
Open Access
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon‐like peptide‐1 receptor agonist use
Peter Rossing, Rajiv Agarwal, Stefan D. Anker, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 407-416
Open Access | Times Cited: 19
Peter Rossing, Rajiv Agarwal, Stefan D. Anker, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 407-416
Open Access | Times Cited: 19
Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
Frederik Flindt Kreiner, Bernt Johan von Scholten, Peter Kurtzhals, et al.
Aging Cell (2023) Vol. 22, Iss. 5
Open Access | Times Cited: 12
Frederik Flindt Kreiner, Bernt Johan von Scholten, Peter Kurtzhals, et al.
Aging Cell (2023) Vol. 22, Iss. 5
Open Access | Times Cited: 12
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis
Peter Rossing, Stephen C. Bain, Heidrun Bosch‐Traberg, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Peter Rossing, Stephen C. Bain, Heidrun Bosch‐Traberg, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 9
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 3
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 3
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Oliver Schnell, Tadej Battelino, Richard M. Bergenstal, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Oliver Schnell, Tadej Battelino, Richard M. Bergenstal, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 7
The Impact of Glucagon-like Peptide-1 Receptor Agonists on Kidney Outcomes: A Meta-Analysis of Randomized Placebo-Controlled Trials
Luís Mendonça, H. B. Moura, Paulo Castro‐Chaves, et al.
Clinical Journal of the American Society of Nephrology (2024)
Closed Access | Times Cited: 1
Luís Mendonça, H. B. Moura, Paulo Castro‐Chaves, et al.
Clinical Journal of the American Society of Nephrology (2024)
Closed Access | Times Cited: 1
Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome
Mengyuan Ge, Judith Molina, Ian M. Tamayo, et al.
Kidney360 (2024) Vol. 5, Iss. 7, pp. 1002-1011
Open Access | Times Cited: 1
Mengyuan Ge, Judith Molina, Ian M. Tamayo, et al.
Kidney360 (2024) Vol. 5, Iss. 7, pp. 1002-1011
Open Access | Times Cited: 1
Strategies to address diabetic kidney disease burden in Mexico: a narrative review by the Mexican College of Nephrologists
Silvia Palomo‐Piñón, Jesús Armando Aguilar-Alonso, Jonathan S. Chávez-Íñiguez, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 1
Silvia Palomo‐Piñón, Jesús Armando Aguilar-Alonso, Jonathan S. Chávez-Íñiguez, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 1
Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial
Liv Vernstrøm, Søren Gullaksen, Steffen S. Sørensen, et al.
Diabetologia (2024) Vol. 67, Iss. 10, pp. 2175-2187
Open Access | Times Cited: 1
Liv Vernstrøm, Søren Gullaksen, Steffen S. Sørensen, et al.
Diabetologia (2024) Vol. 67, Iss. 10, pp. 2175-2187
Open Access | Times Cited: 1
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Frederik Flindt Kreiner, G. Kees Hovingh, Bernt Johan von Scholten
Frontiers in Physiology (2022) Vol. 13
Open Access | Times Cited: 6
Frederik Flindt Kreiner, G. Kees Hovingh, Bernt Johan von Scholten
Frontiers in Physiology (2022) Vol. 13
Open Access | Times Cited: 6
The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease
Zi Guo
Pharmacological Reports (2024) Vol. 76, Iss. 4, pp. 754-779
Closed Access
Zi Guo
Pharmacological Reports (2024) Vol. 76, Iss. 4, pp. 754-779
Closed Access
Challenges and Strategies of Chronic Kidney Disease Care in People with Type 2 Diabetes: A Point of View
Jalal Hassanshahi
Journal of Rafsanjan University of Medical Sciences (2024) Vol. 23, Iss. 4, pp. 267-273
Closed Access
Jalal Hassanshahi
Journal of Rafsanjan University of Medical Sciences (2024) Vol. 23, Iss. 4, pp. 267-273
Closed Access
Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus—Clinical Practice Position Statement of the Polish Society of Nephrology
Marcin Adamczak, Ilona Kurnatowska, Beata Naumnik, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12941-12941
Open Access
Marcin Adamczak, Ilona Kurnatowska, Beata Naumnik, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12941-12941
Open Access
Strategies to Prevent and Delay Chronic Kidney Disease Progression: A Pathway to Sustainability and Green Nephrology
João Venda, Rita Leal
Portuguese Journal of Nephrology & Hypertension (2023) Vol. 37, Iss. 3
Open Access
João Venda, Rita Leal
Portuguese Journal of Nephrology & Hypertension (2023) Vol. 37, Iss. 3
Open Access
Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish Real-World Population-Based study
Ana Palanca, Francisco Javier Ampudia‐Blasco, José Miguel Calderón, et al.
Diabetes Research and Clinical Practice (2023) Vol. 207, pp. 111071-111071
Closed Access
Ana Palanca, Francisco Javier Ampudia‐Blasco, José Miguel Calderón, et al.
Diabetes Research and Clinical Practice (2023) Vol. 207, pp. 111071-111071
Closed Access
